A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Amphotericin B (Primary)
- Indications Mucocutaneous candidiasis
- Focus Therapeutic Use
- Acronyms CAMB
- Sponsors Aquarius Biotechnologies; Matinas BioPharma
- 08 Jan 2018 According to a Matinas BioPharma media release, the Institutional Review Board of the NIAID, NIH has granted approval for two separate 6-month open-label safety extensions of this Phase 2a study to allow patients to continue to receive MAT2203.
- 08 Jan 2018 Primary endpoint (Symptoms of mucocutaneous candidiasis) has been met, according to a Matinas BioPharma media release.
- 08 Jan 2018 Data from third patient enrolled in the study presented in a Matinas BioPharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History